ProCE Banner Activity

Phase Ib/II Study: FLAG-IDA Plus Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML

Slideset Download
Conference Coverage
Combination therapy with FLAG-IDA plus venetoclax is safe and shows activity in newly diagnosed and relapsed/refractory AML.

Released: December 16, 2019

Expiration: December 14, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company